SecBot SecBot
SECBOTREPLAY Home › Report › ESPR

ESPR · Esperion Therapeutics disclosed that the Hart-Scott-Rodino waiting…

Esperion Therapeutics, Inc. · DEFA14A filed Jun 16, 2026 at 16:01 ET

At the news

BULLISHIMPACT 6/10

DEFA14A filed Jun 16, 2026 at 16:01 ET

Esperion Therapeutics disclosed that the Hart-Scott-Rodino waiting period for its pending merger with an affiliate of ArchiMed SAS expired on June 15, 2026, removing a key regulatory condition. The special stockholder meeting to vote on the merger is scheduled for July 8, 2026, and the deal remains subject to stockholder approval and other customary closing conditions.

  • HSR waiting period for the ArchiMed merger expired on June 15, 2026.
  • Special stockholder meeting to vote on the merger is set for July 8, 2026.
  • Merger agreement was entered into on May 1, 2026, with Essence Parent Inc. (ArchiMed affiliate).
  • Closing remains subject to stockholder adoption and other customary conditions.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access